Photo from wikipedia
To the Editor: Skin pain among patients with hidradenitis suppurativa (HS) is prevalent, severe, and a recommended target for treatment. Adalimumab has been approved for moderate-to-severe HS in the United… Click to show full abstract
To the Editor: Skin pain among patients with hidradenitis suppurativa (HS) is prevalent, severe, and a recommended target for treatment. Adalimumab has been approved for moderate-to-severe HS in the United States and Europe on the basis of the PIONEER I and II studies. This letter describes the results of the secondary analyses pertaining to pain reduction during treatment with adalimumab. Both institutional review boardeapproved studies were global, multisite, randomized, double-blind, placebo-controlled, parallel-group clinical trials conducted from 2011 to 2014. In all, 307 and 326 adults with moderate-to-severe HS were randomized to adalimumab, 40 mg every week, or 0.8 mL of
Journal Title: Journal of the American Academy of Dermatology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!